Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Reshaping the model of evidence generation in the era of molecularly driven tissue-independent therapeutics

The HTA perspective: Is tissue-independent approval the next top model?

Date

17 Oct 2020

Session

Reshaping the model of evidence generation in the era of molecularly driven tissue-independent therapeutics

Topics

Bioethical Principles and GCP

Tumour Site

Presenters

Sonia Garcia Perez

Authors

S. Garcia Perez

Author affiliations

Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), 28022 - Madrid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

17 Oct 2020

The clinical perspective: Trials fit for purpose in 2020 and beyond

Presenter: Irene Braña

Session: Reshaping the model of evidence generation in the era of molecularly driven tissue-independent therapeutics

Resources:

Slides

Webcast

17 Oct 2020

The regulatory perspective: How to look for certainty in terra incognita

Presenter: Francesco Pignatti

Session: Reshaping the model of evidence generation in the era of molecularly driven tissue-independent therapeutics

Resources:

Slides

Webcast

17 Oct 2020

Implementation of NGS diagnostics in the NHS: The example of Belgium

Presenter: Marc Van Den Bulcke

Session: Reshaping the model of evidence generation in the era of molecularly driven tissue-independent therapeutics

Resources:

Slides

Webcast

17 Oct 2020

Q&A and live discussion

Presenter: Irene Braña

Session: Reshaping the model of evidence generation in the era of molecularly driven tissue-independent therapeutics

Resources:

Webcast